-transparent.png){kind=logo}
Obese patients encountered in general practice were studied in order to determine whether a long-acting form of diethylpropion hydrochloride (Tenuate Dospan) was more effective than placebo for weight loss. One hundred and two patients completed this double blind, 16-week crossover study. During the first eight weeks, the patients treated with diethylpropion hydrochloride lost significantly (P smaller than 0.001) more weight than the patients treated with placebo (an average of 11-1 lb or 6-4% of their initial weight as compared with 6-2 lb or 3-6% of their initial weight). When the group taking diethylpropion hydrochloride crossed over to placebo for a second eight weeks, they lost an average of 1-5 lb (0-9% of their weight at the start of the second period), while the group who crossed from placebo over to diethylpropion hydrochloride lost an average of 6-7 lb (3-8%). The advantages of diethylpropion hydrochloride over placebo are statistically significant.
D E Carney, and
E D Tweddell
October 1978,
The New Zealand medical journal,
D E Carney, and
E D Tweddell
April 1975,
Current therapeutic research, clinical and experimental,
D E Carney, and
E D Tweddell
March 1968,
The Practitioner,
D E Carney, and
E D Tweddell
April 1966,
The American journal of the medical sciences,
D E Carney, and
E D Tweddell
May 1968,
Current therapeutic research, clinical and experimental,
D E Carney, and
E D Tweddell
October 1988,
The British journal of clinical practice,
D E Carney, and
E D Tweddell
January 1983,
Pharmatherapeutica,
D E Carney, and
E D Tweddell
August 1961,
The American journal of the medical sciences,
D E Carney, and
E D Tweddell
June 1967,
Clinical pediatrics,
D E Carney, and
E D Tweddell
January 1983,
Pharmatherapeutica,
